Generalized Pustular Psoriasis research hub

Effisayil® REP: An open-label, multicenter, single-arm, post-marketing trial (in select countries) to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis (GPP) presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v.

This study looks at a medicine called spesolimab for adults with generalised pustular psoriasis (GPP). It tests how safe and helpful the medicine is when given into a vein for people who have already had it before and are now facing a new flare-up of pus-filled skin blisters.